Tibet Aim Pharm Inc (002826) — Cash Flow-to-Debt Ratio
Tibet Aim Pharm Inc (002826) has a Cash Flow-to-Debt Ratio of 0.34x as of September 2025, meaning its operating cash flow of CN¥87.55 Million could theoretically repay 0% of its total liabilities (CN¥256.63 Million) in one year. See Tibet Aim Pharm Inc financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Tibet Aim Pharm Inc Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Tibet Aim Pharm Inc across 13 annual periods. For the full cash flow conversion analysis, see 002826 cash generation efficiency.
Annual Cash Flow-to-Debt Ratio for Tibet Aim Pharm Inc (2013–2025)
Year-by-year debt coverage analysis for Tibet Aim Pharm Inc. Check 002826 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.61x | CN¥123.72 Million | CN¥201.65 Million | ▼ -0.5% |
| 2024 | 0.62x | CN¥111.57 Million | CN¥180.89 Million | ▼ -34.3% |
| 2023 | 0.94x | CN¥166.88 Million | CN¥177.68 Million | ▲ +268.0% |
| 2022 | 0.26x | CN¥68.45 Million | CN¥268.21 Million | ▼ -75.7% |
| 2021 | 1.05x | CN¥109.52 Million | CN¥104.36 Million | ▲ +127.9% |
| 2020 | 0.46x | CN¥101.74 Million | CN¥220.94 Million | ▲ +42.5% |
| 2019 | 0.32x | CN¥59.20 Million | CN¥183.24 Million | ▲ +238.6% |
| 2018 | 0.10x | CN¥13.31 Million | CN¥139.53 Million | ▼ -84.1% |
| 2017 | 0.60x | CN¥77.29 Million | CN¥128.76 Million | ▼ -4.6% |
| 2016 | 0.63x | CN¥57.18 Million | CN¥90.93 Million | ▲ +416.5% |
| 2015 | -0.20x | CN¥-29.69 Million | CN¥149.44 Million | ▼ -912.3% |
| 2014 | 0.02x | CN¥2.18 Million | CN¥89.30 Million | ▼ -96.2% |
| 2013 | 0.64x | CN¥52.24 Million | CN¥81.43 Million | — |